Meridian Bioscience

Meridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments. The Diagnostics segment consists of manufacturing operations for infectious disease and blood chemistry products and the sale and distribution of diagnostics products domestically and abroad. The Life Science segment distributes bulk antigens, antibodies, polymerase chain reaction/ quantitative PCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Meridian Bioscience is an integrated life science company. The Company is engaged in developing, manufacturing, selling, and distributing clinical diagnostic test kits, for certain gastrointestinal, viral, respiratory, and parasitic infectious diseases; the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/ quantitative polymerase chain reaction (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers, and the contract development and manufacture of proteins and other biologicals under cyclic guanosine monophosphate (cGMP) conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. The Company operates in three segments: U.S. Diagnostics, European Diagnostics, and Life Science.

CINCINNATI and SEOUL, South Korea , Jan. 31, 2023 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, and SD Biosensor, Inc. ("SDB") (KOSE: A137310) and SJL Partners LLC ("SJL") (collectively, the "Consortium"), announced today that they have completed the transaction to acquire Meridian. Under the terms of the merger, Meridian shareholders have the right to receive $34.00 per share in cash.

SD Biosensor and SJL Partners Complete Transaction to Acquire Meridian Bioscience

CINCINNATI , Dec. 12, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced that it has entered into a side letter with the buyer, setting the closing date of Meridian's pending merger for January 31, 2023. As previously disclosed, on July 7, 2022, Meridian, entered into an Agreement and Plan of Merger (the "Merger Agreement") with SD Biosensor, Inc., ("SDB"), Columbus Holding Company ("Parent"), and Madeira Acquisition Corp., a direct wholly owned subsidiary of Parent ("Merger Sub", and together with SDB and Parent, the "Parent Parties," and each individually a "Parent Party").

Meridian Bioscience Announces Anticipated Closing Date of the Pending Merger

Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 33.33% and 2.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Meridian Bioscience (VIVO) Q4 Earnings Surpass Estimates

CINCINNATI , Nov. 22, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2022. Fourth Quarter 2022 Highlights (Comparison to Fourth Quarter Fiscal 2021): Consolidated net revenues totaled $65.7 million, a decrease of 14% year-over-year Diagnostics segment net revenues increased 14% year-over-year to $39.2 million Life Science segment delivered net revenues of $26.5 million, a decrease of 37% Submitted 510(k) for Curian® Shiga Toxin assay Full Fiscal Year 2022 Highlights (Comparison to Full Year Fiscal 2021): Consolidated net revenues of $333.0 million, up 5% year-over-year Diagnostics segment net revenues increased 22% year-over-year to $155.9 million Life Science segment delivered net revenues of $177.1 million, a decrease of 7% Established new Life Science recombinant protein R&D facility in New Jersey with assets acquired from EUPROTEIN, Inc. Diagnostics segment launched two new products: Curian® Campy and Revogene® SARS-CoV-2 EUA Life Science segment launched 17 new molecular products, which completed a full line of sample-specific master mixes for qPCR and LAMP with sensitivity suitable for oncology applications Entered into agreement to be acquired by a Korean Consortium for $34.00 per share, which is expected to close before the end of calendar year 2022 Fourth Quarter Fiscal 2022 Results (Comparison to Fourth Quarter Fiscal 2021) Consolidated net revenues for the fourth quarter of fiscal 2022 decreased 14% to $65.7 million, compared to $76.2 million last year.

MERIDIAN BIOSCIENCE REPORTS FOURTH QUARTER AND FULL YEAR FISCAL 2022 OPERATING RESULTS

Resolute Forest Products

Silverback Therapeutics

Terminix Global Holdings

NEW YORK , Sept. 26, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Terminix Global Holdings, Inc. (NYSE: TMX) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Rentokil Initial plc.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TMX, VIVO, RFP, SBTX

VAALCO Energy

Steel Connect

NEW YORK , Aug. 22, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Resolute Forest Products Inc. (NYSE: RFP)'s  sale to Domtar Corporation. If you are a Resolute shareholder, click here to learn more about your rights and options.

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates RFP, VIVO, EGY, STCN

Biohaven Pharmaceutical Hld

CareMax

Hanger Inc

NEW YORK , Aug. 15, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) 's  sale to Pfizer Inc. for $148.50 per share in cash.

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates BHVN, VIVO, HNGR, CMAX

1Life Healthcare

NEW YORK , Aug. 8, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Meridian Bioscience, Inc. (NASDAQ: VIVO) 's  sale to SD Biosensor, Inc. and SJL Partners LLC for $34.00 per share in cash. If you are a Meridian shareholder, click here to learn more about your rights and options.

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates VIVO, ONEM, HNGR

Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 0% and 1.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Meridian Bioscience (VIVO) Meets Q3 Earnings Estimates

CINCINNATI , Aug. 5, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the third quarter ended June 30, 2022. Third Quarter Fiscal 2022 Highlights (Comparison to Third Quarter Fiscal 2021): Consolidated net revenues totaled $67.8 million, an increase of 7% year-over-year Diagnostics segment net revenues increased 36% year-over-year to a record $42.4 million Life Science segment delivered net revenues of $25.4 million, a decrease of 22% Third Quarter Fiscal 2022 Results (Comparison to Third Quarter Fiscal 2021) Consolidated net revenues for the third quarter of fiscal 2022 were $67.8 million, up 7% from $63.5 million in last year's third quarter.

MERIDIAN BIOSCIENCE REPORTS THIRD QUARTER FISCAL 2022 OPERATING RESULTS

Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Meridian Bioscience (VIVO) to Report a Decline in Earnings: What to Look Out for

CINCINNATI , July 29, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced that it received re-authorization of its Emergency Use Authorization (EUA) for the Revogene® SARS-COV-2 molecular assay from the U.S. Food and Drug Administration (FDA).  Meridian expects to begin shipping this product before the end of its fiscal fourth quarter, ending September 30, 2022.

Meridian Bioscience Receives Re-Authorization from FDA for its Revogene® SARS-CoV-2 Molecular Assay

NEW ORLEANS , July 27, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

MERIDIAN BIOSCIENCE INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Meridian Bioscience, Inc. - VIVO

Wilmington, Delaware--(Newsfile Corp. - July 8, 2022) - Rigrodsky Law, P.A. is investigating Meridian Bioscience, Inc. ("Meridian") (NASDAQ: VIVO) regarding possible breaches of fiduciary duties and other violations of law related to Meridian's agreement to be acquired by SD Biosensor, INC. ("SBD") and SJL Partners LLC ("SJL"). Under the terms of the agreement, Meridian's shareholders will receive approximately $34.00 in cash for each share of Meridian common stock they own.To learn more about this investigation...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Meridian Bioscience, Inc. Buyout

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Meridian Bioscience, Inc. (NasdaqGS: VIVO) to SD Biosensor, Inc. and SJL Partners LLC. Under the terms of the proposed transaction, shareholders of Meridian will receive only $34.00 in cash for each share of Meridian that they own. KSF is seeking to determine whether this consideration and the process that led

MERIDIAN BIOSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Meridian Bioscience, Inc. - VIVO

NEW YORK , July 7, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ: VIVO), in connection with the proposed acquisition of the Company by SD Biosensor, Inc. ("SDB") and SJL Partners LLC ("SJL"). Under the merger agreement, the Company's shareholders will receive $34.00 in cash for each share of Meridian stock owned, leaving SDB owning approximately 60% and SJL owning approximately 40% of Meridian.

SHAREHOLDER ALERT: Weiss Law Investigates Meridian Bioscience, Inc.

MILWAUKEE , July 7, 2022 /PRNewswire/ -- Ademi LLP is investigating Meridian (NASDAQ: VIVO) for possible breaches of fiduciary duty and other violations of law in its transaction with the Consortium.  Click here to learn how to join the action: https://www.ademilaw.com/case/meridian-bioscience-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Meridian Bioscience, Inc. has obtained a Fair Price in its transaction with the Consortium

VIVO stock is a hot topic on Wall Street today, not just because Meridian Biosciences released a fiscal update, but also due to takeover news. The post Meridian Biosciences (VIVO) Stock Trending on $1.5 Billion Buyout Agreement appeared first on InvestorPlace.

Meridian Biosciences (VIVO) Stock Trending on $1.5 Billion Buyout Agreement

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Meridian Bioscience, Inc. (NASDAQ: VIVO) to SD Biosensor, Inc. and SJL Partners LLC for $34.00 per share in cash is fair to Meridian shareholders. Halper Sadeh encourages Meridian shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation

VIVO Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Meridian Bioscience, Inc. Is Fair to Shareholders

Meridian Bioscience Inc. VIVO, +7.02% announced an agreement Thursday to be acquired by a consortium of South Korea-based SD Biosensor Inc. 137310, +2.08% and private equity firm SJL Partners LLC in a cash deal valued at $1.53 billion. Under terms of the deal, Meridian shareholders will receive $34.00 in cash for each Meridian share they own, representing a 1.3% premium to Wednesday's closing price of $33.55.

Meridian Bioscience agrees to $1.5 billion buyout by SD Biosensor, SJL Partners

Shareholders to Receive $34.00 Per Share in Cash, Providing Immediate, Compelling and Certain Value Transaction Follows Deliberate Review, Including Outreach to Potential Strategic and Financial Partners CINCINNATI and SEOUL, South Korea , July 7, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, and SD Biosensor, Inc. ("SDB") (KOSE: A137310) and SJL Partners LLC ("SJL") (collectively, the "Consortium") announced today that they have entered into a definitive merger agreement whereby a newly formed affiliate vehicle of the Consortium will acquire Meridian in an all-cash transaction valued at approximately $1.53 billion. Under the terms of the agreement, Meridian shareholders will receive $34.00 per share in cash, which represents a premium of approximately 32% over Meridian's closing stock price on the day before the Consortium's first offer before the market open on March 18, 2022 (closing price on March 17, 2022 was $25.67) and a premium of 16% based on the one-month average price per share of common stock commencing June 7, 2022.

Meridian Bioscience, Inc. Enters into Agreement to Be Acquired by SD Biosensor and SJL Partners in $1.53 Billion All-Cash Transaction

CINCINNATI , July 7, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, today provided preliminary results for its third quarter of fiscal 2022. For the third quarter of fiscal 2022, preliminary unaudited net revenues are expected to be between $66 million and $69 million.

Meridian Bioscience Announces Preliminary Results for Fiscal 2022 Third Quarter

100% technical buy signals. 8 new highs and up 15.79% in the last month.

Meridian Bioscience Is Not Your Average Life Science Company

CINCINNATI , June 20, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today two new sample-specific master mixes, Lyo-Ready™ Direct DNA qPCR Stool Mix, and Lyo-Ready™ Direct RNA/DNA qPCR Stool Mix. These innovative master mixes improve the molecular detection of DNA and RNA from crude fecal specimens while allowing room temperature stabilization of diagnostic assays.

Meridian Launches New qPCR Master Mixes for Stool Samples to Accelerate Development of Molecular Assays

Meridian Bioscience (VIVO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

News for Meridian Bioscience Stock (VIVO)